<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169711</url>
  </required_header>
  <id_info>
    <org_study_id>AROHIF21001</org_study_id>
    <nct_id>NCT04169711</nct_id>
  </id_info>
  <brief_title>Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma</brief_title>
  <official_title>A Phase 1b Dose-Finding Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also&#xD;
      referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of&#xD;
      patients with advanced clear cell renal cell carcinoma (ccRCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment</measure>
    <time_frame>Up to 2 years from first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ARO-HIF2: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-HIF2: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to 4 Hours (AUC0-4)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to the Last Measurable Concentration at a Time=t, Using a Specified Trapezoidal Rule (AUC0-t)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to Infinity (AUCinf)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-HIF2: Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance Derived From Intravenous Dose/Area Under the Plasma Concentration Versus Time Curve (CL)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in the Urine Over One Dosing Interval Through 4 Hours Post- Dose (Ae, 0-4)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance Calculated by Ae, 0-4 h/AUC0-4h (CLR)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction Excreted (or Equivalently the Percent of Dose Excreted) in the Urine, Calculated by 100 X (Ae, 0-4 h/Dose)</measure>
    <time_frame>Up to Week 2: predose and up to 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Baseline until disease progression, up to 2 years</time_frame>
    <description>Percentage of participants with a best overall response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Baseline until disease progression, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Baseline until disease progression, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>ARO-HIF2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARO-HIF2</intervention_name>
    <description>Multiple doses of ARO-HIF2 by intravenous infusion</description>
    <arm_group_label>ARO-HIF2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test, cannot be&#xD;
             breastfeeding and must be willing to use contraception&#xD;
&#xD;
          -  Willing to provide written informed consent and to comply with study requirements&#xD;
&#xD;
          -  Histologically confirmed locally advanced or metastatic clear cell renal cell&#xD;
             carcinoma that has progressed during or after at least two prior therapeutic regimens&#xD;
             which must include vascular endothelial growth factor (VEGF)-targeted therapy and&#xD;
             checkpoint inhibitor therapy or that has otherwise failed such therapies, is&#xD;
             measurable disease per RECIST 1.1 criteria, is biopsy accessible&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1&#xD;
&#xD;
          -  Estimated life expectancy of longer than 3 months&#xD;
&#xD;
          -  Adequate organ function at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of untreated brain metastasis or leptomeningeal disease or spinal cord&#xD;
             compression&#xD;
&#xD;
          -  Failure to recover from reversible effects of prior anti-cancer therapy&#xD;
&#xD;
          -  Has received systemic therapy or radiation therapy within 2 weeks prior to first dose&#xD;
&#xD;
          -  History of solid organ or stem cell transplantation&#xD;
&#xD;
          -  Current use of anti-VEGF or mammalian target of rapamycin (mTOR) agents, or chronic&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Any prior use of hypoxia inducible factor 2 (HIF2) inhibitors within 6 months prior to&#xD;
             first dose&#xD;
&#xD;
          -  Current use of immune checkpoint inhibitors&#xD;
&#xD;
          -  Use of an investigational agent or device within 2 weeks prior to dosing, or current&#xD;
             participation in an investigational study&#xD;
&#xD;
          -  Known HIV, hepatitis B or hepatitis C&#xD;
&#xD;
          -  History of other clinically meaningful disease&#xD;
&#xD;
          -  Major surgery within 4 weeks of Screening&#xD;
&#xD;
          -  Active malignancy requiring therapy other than ccRCC within 3 years of study entry&#xD;
&#xD;
        Note: Other eligibility criteria may apply per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>1-626-304-3400</phone>
    <email>clinicaltrials@arrowheadpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

